Emilie is our Director, Strategy and Portfolio Development. In her current role, she works alongside senior management to develop a value creation business strategy for the company, generating analyses and insights in therapeutic areas of interest to ensure that Avilar’s pipeline and assets are best prioritized to support the organization’s short and long-term goals. Prior to joining Avilar, she was a senior team leader at the Gerson Lehrman Group (2015-2020, London and Boston), where she led an international team of PhDs working with global life sciences equity analysts, and private and public investors on their commercial and scientific due diligence. Emilie is a scientist by training, with a PhD in molecular and cell biology from the Wellcome Trust Centre for Cell Biology, University of Edinburgh, UK, working under Robin Allshire and Mike Tyers, and a MSc in molecular biology from the University of Montreal, Canada.
